Print Friendly and PDF
Baby boomers offer their thoughts and observations on spring
Attorneys generals intervene in lawsuit to protect retirees from dishonest financial advisors

Rheumatoid arthritis medication shouldn’t be approved by FDA, consumer group says

RheumatoidArthritis2Baricitinib, a medication that would be used to treat adults with rheumatoid arthritis, shouldn’t be approved by the U.S. Food and Drug Administration because it causes unique life-threatening harms and lacks any unique benefit over the similar FDA-approved medication tofacitinib, Michael Carome, M.D., director of Public Citizen’s Health Research Group, said Monday.

The FDA rejected the medication in April 2017 after concluding that it has an unfavorable risk-benefit profile. Data from randomized clinical trials show that baricitinib, which was developed by Eli Lilly and Co., can cause potentially fatal blood clots, a risk not seen with similar rheumatoid arthritis medications. The company resubmitted an application for approval of the product but didn’t provide any new data that alters the agency’s original conclusion.

Approval of baricitinib would show blatant disregard for the public health principles underlying the FDA’s regulatory authority, Carome said.


Feed You can follow this conversation by subscribing to the comment feed for this post.

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Your comment could not be posted. Error type:
Your comment has been posted. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.


Post a comment

Your Information

(Name and email address are required. Email address will not be displayed with the comment.)